RecruitingPhase 3NCT05325580
Intravenous Magnesium Sulfate Vs Placebo to Treat Non -Traumatic Acute Headaches in the Emergency Department
Intravenous Magnesium Sulfate Vs Placebo to Treat Non-traumatic Acute Headaches in the Emergency Department
Sponsor
University of Monastir
Enrollment
424 participants
Start Date
Dec 1, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
Intravenous Magnesium Sulfate Vs Placebo to Treat Non -Traumatic Acute Headaches in the Emergency Department
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Inclusion Criteria5
- informed consent
- age >18 years
- Acute non-traumatic acute headaches
- patients treated in ED
- Magnesium sulfate and aspirin administered intravenously (IV)
Exclusion Criteria9
- Current regular use of analgesics, anticonvulsants or antidepressants
- Renal disorder with a low glomerular filtration rate (<60 ml/min)
- Neuromuscular disorder
- Pregnant woman
- Contrindication
- Allergy to NSAID
- Traumatic Headache
- Chronic headache ( headache occurring at least 15 days per month for at least 3 months)
- Hemodynamic instability
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMagnesium sulfate
magnesium group 1g paracetamol + 20 min infusion of 2 g magnesium in 150 ml of saline serum and Placebo Group 1g paracetamol + 20 min infusion of 150 ml of saline serum
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05325580